Literature DB >> 26655599

Prelimbic Stimulation Ameliorates Depressive-Like Behaviors and Increases Regional BDNF Expression in a Novel Drug-Resistant Animal Model of Depression.

Hagar Moshe1, Ram Gal1, Noam Barnea-Ygael1, Tatiana Gulevsky1, Uri Alyagon1, Abraham Zangen2.   

Abstract

BACKGROUND: Approximately one third of all major depression patients fail to respond to conventional pharmacological antidepressants, and brain stimulation methods pose a promising alternative for this population. Recently, based on repeated multifactorial selective inbreeding of rats for depressive-like behaviors, we introduced a novel animal model for MDD. Rats from this Depressive Rat Line (DRL) exhibit inherent depressive-like behaviors, which are correlated with lower levels of brain-derived neurotrophic factor (BDNF) in specific brain regions. In addition, DRL rats do not respond to antidepressant medication but respond to electroconvulsive treatment, and they can thus be utilized to test the effectiveness of brain stimulation on hereditary, medication-resistant depressive-like behaviors.
OBJECTIVE: To test the effect of sub-convulsive electrical stimulation (SCES) of the prelimbic cortex, using TMS-like temporal pattern of stimulation, on depressive-like behaviors and regional BDNF levels in DRL rats.
METHODS: SCES sessions were administered daily for 10 days through chronically implanted electrodes. Temporal stimulation parameters were similar to those used in TMS for major depression in human patients. Depressive-like behaviors were assayed after treatment, followed by brain extraction and regional BDNF measurements.
RESULTS: SCES normalized both the depressive-like behaviors and the reduced BDNF levels observed in DRL rats. Correlation analyses suggest that changes in specific behaviors are mediated, at least in part, by BDNF expression in reward-related brain regions.
CONCLUSIONS: Brain stimulation is effective in a drug-resistant, inherited animal model for depression. BDNF alterations in specific regions may mediate different antidepressant effects.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; Antidepressant; BDNF; Brain stimulation; Major depressive disorder; Prefrontal cortex

Mesh:

Substances:

Year:  2015        PMID: 26655599     DOI: 10.1016/j.brs.2015.10.009

Source DB:  PubMed          Journal:  Brain Stimul        ISSN: 1876-4754            Impact factor:   8.955


  5 in total

Review 1.  Deep brain stimulation for treatment-resistant depression: an integrative review of preclinical and clinical findings and translational implications.

Authors:  M P Dandekar; A J Fenoy; A F Carvalho; J C Soares; J Quevedo
Journal:  Mol Psychiatry       Date:  2018-02-27       Impact factor: 15.992

Review 2.  Role of Ketamine in the Treatment of Psychiatric Disorders.

Authors:  Sahar Derakhshanian; Maxine Zhou; Alexander Rath; Rachel Barlow; Sarah Bertrand; Caroline DeGraw; Christopher Lee; Jamal Hasoon; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-22

3.  Genetic Ablation of the Inducible Form of Nitric Oxide in Male Mice Disrupts Immature Neuron Survival in the Adult Dentate Gyrus.

Authors:  Gabriel G Fernandes; Karla C M Costa; Davi S Scomparin; Juliana B Freire; Francisco S Guimarães; Alline C Campos
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

4.  Focal electrical stimulation on an alcohol disorder model using magnetic resonance imaging-compatible chronic neural monopolar carbon fiber electrodes.

Authors:  Alejandra Lopez-Castro; Diego Angeles-Valdez; Gerardo Rojas-Piloni; Eduardo A Garza-Villarreal
Journal:  Front Neurosci       Date:  2022-09-29       Impact factor: 5.152

Review 5.  Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines.

Authors:  Simone Rossi; Andrea Antal; Sven Bestmann; Marom Bikson; Carmen Brewer; Jürgen Brockmöller; Linda L Carpenter; Massimo Cincotta; Robert Chen; Jeff D Daskalakis; Vincenzo Di Lazzaro; Michael D Fox; Mark S George; Donald Gilbert; Vasilios K Kimiskidis; Giacomo Koch; Risto J Ilmoniemi; Jean Pascal Lefaucheur; Letizia Leocani; Sarah H Lisanby; Carlo Miniussi; Frank Padberg; Alvaro Pascual-Leone; Walter Paulus; Angel V Peterchev; Angelo Quartarone; Alexander Rotenberg; John Rothwell; Paolo M Rossini; Emiliano Santarnecchi; Mouhsin M Shafi; Hartwig R Siebner; Yoshikatzu Ugawa; Eric M Wassermann; Abraham Zangen; Ulf Ziemann; Mark Hallett
Journal:  Clin Neurophysiol       Date:  2020-10-24       Impact factor: 4.861

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.